| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
ROSTOCK, Germany—In vitro profiling specialist Bionas GmbH and Schwein, Germany-based PRIMACYT Cell Culture Technology GmbH announced a cooperative agreement that will see the companies develop a hepatocyte-based assay that will help pharmaceutical firms predict liver toxicity in test compounds. The deal should allow the companies to grab a significant chunk of the growing ADMET market that according to a report by Frost & Sullivan, is expected to reach $776 million by 2011 in Europe alone.
 
"Our study using primary human hepatocytes and Bionas 2500 analyzing system shows very promising results and could be ideally suited to predict hepatotoxic effects in vitro," says Dr. Ralf Ehret, Bionas general manager.
 
PRIMACYT will provide primary human hepatocyte cell lines and media to be used with Bionas' collagen-coated metabolic chips. The chips measure a variety of metabolic processes, allowing researchers to detect changes in real time in response to drug candidates.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue